Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Beam Therapeutics Inc.BEAM · Entity 4227 | Director | June 04, 2025 | June 06, 2025 |
| Denali Therapeutics Inc.DNLI · Entity 1735 | Chief Medical Officer | August 12, 2025 | August 15, 2025 |
| ELI LILLY & CoLLY · Entity 2794 | EVP & Pres, Lilly Neuroscience | December 31, 2025 | January 06, 2026 |
| Royalty Pharma plcRPRX · Entity 3100 | Director | June 05, 2026 | June 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Beam Therapeutics Inc.
Report date June 04, 2025 · Filed June 06, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.15 · Expires 2035-06-04 | Direct | 33,662 |
Reported balance
After 2025-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-04 · Grant · Acquired 33,662 · Balance 33,662 F1: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.
Denali Therapeutics Inc.
Report date August 12, 2025 · Filed August 15, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 216,585 |
Last balance in matching sequence
After 2025-08-13 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2025-08-12 · Sale · Disposed 2,937 · Balance 217,391 F1: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units. F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $13.34 to $13.58 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3: Includes 128,405 Unvested RSUs. Row 2 · 2025-08-13 · Sale · Disposed 806 · Balance 216,585 F4: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted December 11, 2024. F3: Includes 128,405 Unvested RSUs. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 183,219 |
Reported balance
Holding disclosure · report date 2025-08-12 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 183,219 F5: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 25,000 |
Reported balance
Holding disclosure · report date 2025-08-12 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 25,000 F6: The shares are held of record by The Rohatgi-Ho Irrevocable GST Trust for the benefit of the Reporting Person's children. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units.
F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $13.34 to $13.58 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3: Includes 128,405 Unvested RSUs.
F4: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted December 11, 2024.
F5: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.
F6: The shares are held of record by The Rohatgi-Ho Irrevocable GST Trust for the benefit of the Reporting Person's children.
ELI LILLY & Co
Report date December 31, 2025 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2025-12-31 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F2: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. F1: The restricted stock units vest in three installments, 904.631 on December 1, 2026, 932.044 on December 1, 2027, and 904.631 on December 1, 2028. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units vest in three installments, 904.631 on December 1, 2026, 932.044 on December 1, 2027, and 904.631 on December 1, 2028.
F2: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.
Royalty Pharma plc
Report date June 05, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary SharesSEC Table I · non-derivative | Direct | 4,545 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 4,545 · Balance 4,545 F1: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. |
| Class A Ordinary SharesSEC Table I · non-derivative | IndirectSee footnote | 8,558 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 8,558 F2: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.
F2: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
NGM BIOPHARMACEUTICALS INC
Report date April 05, 2024 · Filed April 08, 2024
Section 16 reporting ended · disclosed 2024-04-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.69 · Expires 2033-05-09 | Direct | 0 |
Reported balance
After 2024-04-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-04-05 · Disposition to issuer · Disposed 78,407 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price"). F2: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.35 · Expires 2032-05-17 | Direct | 0 |
Reported balance
After 2024-04-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-04-05 · Disposition to issuer · Disposed 24,222 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price"). F2: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.24 · Expires 2031-06-07 | Direct | 0 |
Reported balance
After 2024-04-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-04-05 · Disposition to issuer · Disposed 19,619 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price"). F2: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.66 · Expires 2030-06-04 | Direct | 0 |
Reported balance
After 2024-04-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-04-05 · Disposition to issuer · Disposed 39,515 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price"). F2: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price").
F2: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 11, 2022 Filed Feb 15, 2022 23:53 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,918 | $34.71 | $101,283.78 |
DisclosureSEC source: 0001714899-22-000039 · wf-form4_164496920633802.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 170,663 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $34.44 to $35.13 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Reflects the issuance of shares to the Rohatgi-Ho Family 2009 Revocable Trust in connection with the vesting of 7,469 restricted stock units held by the Reporting Person. F4 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 22:16 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,423 | $37.10 | $52,791.45 |
DisclosureSEC source: 0001714899-22-000033 · wf-form4_164461775653814.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 166,112 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $36.71 to $37.40 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Reflects the issuance of shares to the Rohatgi-Ho Family 2009 Revocable Trust in connection with the vesting of 4250 restricted stock units held by the Reporting Person. F4 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 23:05 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,845 | $44.78 | $127,399.10 |
DisclosureSEC source: 0001714899-22-000006 · wf-form4_164159673634515.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 163,285 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $44.5101 to $45.05 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Reflects the issuance of shares to the Rohatgi-Ho Family 2009 Revocable Trust in connection with the vesting of 7500 restricted stock units held by the Reporting Person. F4 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:03 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 93,000 | $0.00 Strike: $47.27 | $0.00 |
DisclosureSEC source: 0001714899-22-000003 · wf-form4_164142741424082.xml · derivative · entry 4 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,000 Underlying: Common Stock · 93,000 shares Expires 2032-01-02 F5 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 3, 2023, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:03 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 31,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001714899-22-000003 · wf-form4_164142741424082.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,316 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on January 3, 2023 (the "Vesting Commencement Date") and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · balance_after: Includes 106,906 restricted stock units. Read SEC document |
| December 06, 2021 Filed Dec 8, 2021 22:35 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,476 | $42.52 | $62,759.52 |
DisclosureSEC source: 0001714899-21-000115 · wf-form4_163900291036377.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,316 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · ownership.direct: Includes 75,906 restricted stock units. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 22:26 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 6,143 | $48.91 | $300,454.13 |
DisclosureSEC source: 0001714899-21-000088 · wf-form4_162993039163357.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 158,630 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| August 19, 2021 Filed Aug 24, 2021 00:25 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,144 | $49.91 | $57,097.04 |
DisclosureSEC source: 0001714899-21-000087 · wf-form4_162976473844672.xml · nonDerivative · entry 2 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 164,773 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $49.80 to $50.10 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F4 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| August 19, 2021 Filed Aug 24, 2021 00:25 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,402 | $49.31 | $69,132.62 |
DisclosureSEC source: 0001714899-21-000087 · wf-form4_162976473844672.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 165,917 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $48.79 to $49.78 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Reflects the issuance of shares to the Rohatgi-Ho Family 2009 Revocable Trust in connection with the vesting of 5000 restricted stock units held by the Reporting Person. F4 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 11:57 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 6,877 | $0.00 Strike: $87.91 | $0.00 |
DisclosureSEC source: 0000899243-21-023469 · doc4.xml · derivative · entry 1 Ho Carole · CIK 0001724605 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,877 Underlying: Common Stock · 6,877 shares Expires 2031-06-10 F1 · derivative.exercise_date: The option vests in full on the first anniversary of the date of grant, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 17:39 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | GrantStock Option (Right to Buy) · Derivative | 19,619 | $0.00 Strike: $17.24 | $0.00 |
DisclosureSEC source: 0001209191-21-039593 · doc4.xml · derivative · entry 1 Ho Carole · CIK 0001724605 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,619 Underlying: Common Stock · 19,619 shares Expires 2031-06-07 F1 · derivative.exercise_date: The stock option shall vest in four (4) approximately equal quarterly installments, such that the option shall be fully vested on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day prior to the Issuer's next annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Amended and Restated 2018 Equity Incentive Plan) on each applicable vesting date. Read SEC document |
| March 29, 2021 Filed Mar 31, 2021 22:30 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,822 | $54.62 | $154,126.35 |
DisclosureSEC source: 0001209191-21-023846 · doc4.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 162,319 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $54.08 to $54.93 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:21 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 68 | $71.27 | $4,846.36 |
DisclosureSEC source: 0001209191-21-016857 · doc4.xml · nonDerivative · entry 7 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 165,141 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F3 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:21 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 125 | $70.07 | $8,758.13 |
DisclosureSEC source: 0001209191-21-016857 · doc4.xml · nonDerivative · entry 6 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 165,209 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $70.03 to $70.32 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:21 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 208 | $68.87 | $14,323.92 |
DisclosureSEC source: 0001209191-21-016857 · doc4.xml · nonDerivative · entry 5 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 165,334 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F3 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:21 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,320 | $68.01 | $89,771.88 |
DisclosureSEC source: 0001209191-21-016857 · doc4.xml · nonDerivative · entry 4 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 165,542 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $67.45 to $68.335 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:21 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,173 | $67.07 | $78,669.59 |
DisclosureSEC source: 0001209191-21-016857 · doc4.xml · nonDerivative · entry 3 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 166,862 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $66.375 to $67.35 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:21 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,871 | $65.74 | $188,725.19 |
DisclosureSEC source: 0001209191-21-016857 · doc4.xml · nonDerivative · entry 2 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 168,035 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $65.26 to $66.21 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:21 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,327 | $64.54 | $85,645.91 |
DisclosureSEC source: 0001209191-21-016857 · doc4.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 170,906 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $64.20 to $65.155 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| February 11, 2021 Filed Feb 17, 2021 00:43 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 400 | $71.49 | $28,594.40 |
DisclosureSEC source: 0001209191-21-011010 · doc4.xml · nonDerivative · entry 2 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 172,233 F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $71.01 to $71.705 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 7,468 shares acquired pursuant to vesting of restricted stock units and issued directly to the Rohatgi-Ho Family 2009 Revocable Trust. F4 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| February 11, 2021 Filed Feb 17, 2021 00:43 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,756 | $70.17 | $193,377.50 |
DisclosureSEC source: 0001209191-21-011010 · doc4.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 172,633 F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $69.79 to $70.74 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 7,468 shares acquired pursuant to vesting of restricted stock units and issued directly to the Rohatgi-Ho Family 2009 Revocable Trust. F4 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 00:10 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 100 | $76.00 | $7,600.00 |
DisclosureSEC source: 0001209191-21-009888 · doc4.xml · nonDerivative · entry 4 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 167,921 F3 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 00:10 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 364 | $75.10 | $27,337.13 |
DisclosureSEC source: 0001209191-21-009888 · doc4.xml · nonDerivative · entry 3 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 168,021 F3 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $74.96 to $75.21 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 00:10 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,006 | $74.40 | $74,847.41 |
DisclosureSEC source: 0001209191-21-009888 · doc4.xml · nonDerivative · entry 2 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 168,385 F3 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $73.96 to $74.75 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| February 07, 2021 Filed Feb 12, 2021 00:10 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionRestricted Stock Units · Derivative | 4,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009888 · doc4.xml · derivative · entry 7 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 4,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F7 · derivative.exercise_date: 25% of the restricted stock units vested on February 7, 2020 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F7 · derivative.expiration_date: 25% of the restricted stock units vested on February 7, 2020 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| February 07, 2021 Filed Feb 12, 2021 00:10 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 4,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009888 · doc4.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 169,391 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:54 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $70.86 | $0.00 |
DisclosureSEC source: 0001209191-21-002351 · doc4.xml · derivative · entry 2 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2031-01-03 F3 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 4, 2022, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:54 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantRestricted Stock Units · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002351 · doc4.xml · derivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · derivative.exercise_date: 25% of the restricted stock units shall vest on January 4, 2022 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · derivative.expiration_date: 25% of the restricted stock units shall vest on January 4, 2022 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| October 09, 2020 Filed Oct 13, 2020 22:45 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001209191-20-054727 · doc4.xml · derivative · entry 9 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,240 Underlying: Common Stock · 30,000 shares Expires 2027-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Of the total 187,500 shares granted, 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vest monthly thereafter. Read SEC document |
| October 09, 2020 Filed Oct 13, 2020 22:45 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 19,535 | $41.51 | $810,897.85 |
DisclosureSEC source: 0001209191-20-054727 · doc4.xml · nonDerivative · entry 5 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 166,617 F2 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $41.11 to $41.81 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F1 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| October 09, 2020 Filed Oct 13, 2020 22:45 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 10,465 | $40.68 | $425,716.20 |
DisclosureSEC source: 0001209191-20-054727 · doc4.xml · nonDerivative · entry 4 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 186,152 F2 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $40.11 to $41.09 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F1 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| October 09, 2020 Filed Oct 13, 2020 22:45 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 30,000 | $5.28 | $158,400.00 |
DisclosureSEC source: 0001209191-20-054727 · doc4.xml · nonDerivative · entry 3 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 196,617 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| October 08, 2020 Filed Oct 13, 2020 22:45 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 9,886 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001209191-20-054727 · doc4.xml · derivative · entry 8 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,240 Underlying: Common Stock · 9,886 shares Expires 2027-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Of the total 187,500 shares granted, 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vest monthly thereafter. Read SEC document |
| October 08, 2020 Filed Oct 13, 2020 22:45 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 13,020 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001209191-20-054727 · doc4.xml · derivative · entry 7 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,035 Underlying: Common Stock · 13,020 shares Expires 2026-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Of the total 125,000 shares granted, 25% of the shares subject to the option vested on July 2, 2017 and an additional 1/48 of the shares vest monthly thereafter. Read SEC document |
| October 08, 2020 Filed Oct 13, 2020 22:45 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 22,906 | $40.12 | $918,988.72 |
DisclosureSEC source: 0001209191-20-054727 · doc4.xml · nonDerivative · entry 2 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 166,617 F2 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $40.00 to $40.32 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F1 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| October 08, 2020 Filed Oct 13, 2020 22:45 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 22,906 | $5.28 | $120,943.68 |
DisclosureSEC source: 0001209191-20-054727 · doc4.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 189,523 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| September 10, 2020 Filed Sep 15, 2020 01:38 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 3,689 | $31.00 | $114,359.00 |
DisclosureSEC source: 0001209191-20-050357 · doc4.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 165,141 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| August 21, 2020 Filed Aug 25, 2020 00:38 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Tax withholdingCommon Stock | 1,954 | $32.88 | $64,247.52 |
DisclosureSEC source: 0001209191-20-048175 · doc4.xml · nonDerivative · entry 2 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,511 F2 · kind: Shares withheld to satisfy the tax obligations by the reporting person in connection with the vesting of restricted stock units. F3 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $32.835 to $32.885 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| August 20, 2020 Filed Aug 25, 2020 00:38 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionRestricted Stock Units · Derivative | 5,643 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-048175 · doc4.xml · derivative · entry 5 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,643 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Common Stock of the Issuer. F6 · derivative.exercise_date: 50% of the shares vested on August 20, 2019 and the remaining 50% of the shares vested on August 20, 2020. F6 · derivative.expiration_date: 50% of the shares vested on August 20, 2019 and the remaining 50% of the shares vested on August 20, 2020. Read SEC document |
| August 20, 2020 Filed Aug 25, 2020 00:38 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 5,643 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-048175 · doc4.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,465 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Common Stock of the Issuer. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:20 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-047795 · doc4.xml · derivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · derivative.exercise_date: 25% of the restricted stock units shall vest on August 18, 2021 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · derivative.expiration_date: 25% of the restricted stock units shall vest on August 18, 2021 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 17:08 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | GrantStock Option (Right to Buy) · Derivative | 39,515 | $0.00 Strike: $20.66 | $0.00 |
DisclosureSEC source: 0001209191-20-035314 · doc4.xml · derivative · entry 1 Ho Carole · CIK 0001724605 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,515 Underlying: Common Stock · 39,515 shares Expires 2030-06-04 F1 · derivative.exercise_date: One third of the shares subject to the option shall vest on June 5, 2021, and the remainder of the shares shall vest quarterly over the following two years, such that the grant will be fully vested on June 5, 2023, subject to the Reporting Person's Continuous Service (as defined in the Amended and Restated 2018 Equity Incentive Plan) on each applicable vesting date. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 22:18 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,428 | $19.48 | $27,817.44 |
DisclosureSEC source: 0001209191-20-022239 · doc4.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,822 F1 · kind: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.44 to $19.48 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 23:01 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 142,000 | $0.00 Strike: $24.81 | $0.00 |
DisclosureSEC source: 0001209191-20-008922 · doc4.xml · derivative · entry 2 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,000 Underlying: Common Stock · 142,000 shares Expires 2030-02-09 F3 · derivative.exercise_date: 25% of the shares subject to the option shall vest on February 10, 2021, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 23:01 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantRestricted Stock Units · Derivative | 29,874 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-008922 · doc4.xml · derivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,874 Underlying: Common Stock · 29,874 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · derivative.exercise_date: 25% of the restricted stock units shall vest on February 10, 2021 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · derivative.expiration_date: 25% of the restricted stock units shall vest on February 10, 2021 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| February 07, 2020 Filed Apr 1, 2020 22:14 UTC Amendment | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionRestricted Stock Units · Derivative | 4,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-022235 · doc4a.xml · derivative · entry 2 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,750 Underlying: Common Stock · 4,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Common Stock of the Issuer. F2 · derivative.exercise_date: 25% of the restricted stock units vested on February 7, 2020 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · derivative.expiration_date: 25% of the restricted stock units vested on February 7, 2020 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| February 07, 2020 Filed Apr 1, 2020 22:14 UTC Amendment | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 4,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-022235 · doc4a.xml · nonDerivative · entry 1 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Common Stock of the Issuer. Read SEC document |
| December 23, 2019 Filed Dec 24, 2019 00:35 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 3,464 | $20.01 | $69,314.64 |
DisclosureSEC source: 0001209191-19-061843 · doc4.xml · nonDerivative · entry 6 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F5 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F8 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares sold ranging from $20.00 to $20.08 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F1 · balance_after: The shares acquired on August 20, 2019 as reported on the Form 4 filed on August 22, 2019 were incorrectly attributed to the shares held jointly by Carole Ho and Rajat Rohatgi. Column 5 of Table I has been updated to reflect the current balance of shares held by Carole Ho and Rajat Rohatgi, as well as shares held directly in the Reporting Person's sole capacity. Read SEC document |
| December 20, 2019 Filed Dec 24, 2019 00:35 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 860 | $20.00 | $17,200.00 |
DisclosureSEC source: 0001209191-19-061843 · doc4.xml · nonDerivative · entry 5 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,464 F5 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares sold ranging from $20.00 to $20.04 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F1 · balance_after: The shares acquired on August 20, 2019 as reported on the Form 4 filed on August 22, 2019 were incorrectly attributed to the shares held jointly by Carole Ho and Rajat Rohatgi. Column 5 of Table I has been updated to reflect the current balance of shares held by Carole Ho and Rajat Rohatgi, as well as shares held directly in the Reporting Person's sole capacity. Read SEC document |
| December 19, 2019 Filed Dec 24, 2019 00:35 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 2,566 | $20.00 | $51,320.00 |
DisclosureSEC source: 0001209191-19-061843 · doc4.xml · nonDerivative · entry 4 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,324 F5 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares sold ranging from $20.00 to $20.07 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F1 · balance_after: The shares acquired on August 20, 2019 as reported on the Form 4 filed on August 22, 2019 were incorrectly attributed to the shares held jointly by Carole Ho and Rajat Rohatgi. Column 5 of Table I has been updated to reflect the current balance of shares held by Carole Ho and Rajat Rohatgi, as well as shares held directly in the Reporting Person's sole capacity. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.